82 related articles for article (PubMed ID: 27387230)
1. The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells in vitro and in vivo.
Jiang Y; Meng Q; Chen B; Shen H; Yan B; Sun B
Biochem Biophys Res Commun; 2016 Sep; 478(1):293-299. PubMed ID: 27387230
[TBL] [Abstract][Full Text] [Related]
2. Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity.
Zhao X; Sun B; Zhang J; Zhang R; Zhang Q
Biochem Biophys Res Commun; 2016 Oct; 479(2):166-172. PubMed ID: 27562715
[TBL] [Abstract][Full Text] [Related]
3. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
4. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
Hong SW; Shin JS; Moon JH; Jung SA; Koh DI; Ryu Y; Park YS; Kim DY; Park SS; Hong JK; Kim EH; Kim MJ; Jeong HR; Bae IH; Ahn YG; Suh KH; Cho IJ; Kang JS; Hong YS; Lee JS; Jin DH; Kim TW
Invest New Drugs; 2020 Dec; 38(6):1696-1706. PubMed ID: 32462369
[TBL] [Abstract][Full Text] [Related]
6. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
DiPersio JF; Erba HP; Larson RA; Luger SM; Tallman MS; Brill JM; Vuagniaux G; Rouits E; Sorensen JM; Zanna C
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):443-9. PubMed ID: 25842225
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
8. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
[TBL] [Abstract][Full Text] [Related]
9. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.
Thibault B; Genre L; Le Naour A; Broca C; Mery E; Vuagniaux G; Delord JP; Wiedemann N; Couderc B
Sci Rep; 2018 Dec; 8(1):17862. PubMed ID: 30552344
[TBL] [Abstract][Full Text] [Related]
10. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.
Cai Q; Sun H; Peng Y; Lu J; Nikolovska-Coleska Z; McEachern D; Liu L; Qiu S; Yang CY; Miller R; Yi H; Zhang T; Sun D; Kang S; Guo M; Leopold L; Yang D; Wang S
J Med Chem; 2011 Apr; 54(8):2714-26. PubMed ID: 21443232
[TBL] [Abstract][Full Text] [Related]
11. The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1).
Leja-Szpak A; Góralska M; Link-Lenczowski P; Czech U; Nawrot-Porąbka K; Bonior J; Jaworek J
Anticancer Agents Med Chem; 2019; 19(17):2079-2090. PubMed ID: 30987575
[TBL] [Abstract][Full Text] [Related]
12. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
13. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
[TBL] [Abstract][Full Text] [Related]
14. [X-linked inhibitor of apoptosis protein (XIAP) and Survivin suppression on human pancreatic cancer cells Panc-1 proliferation and chemosensitivety].
Zai HY; Yi XP; Li YX; You XY; Cao LP; Liu H
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):242-9. PubMed ID: 23591345
[TBL] [Abstract][Full Text] [Related]
15. Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of Apoptosis.
Díaz Osterman CJ; Gonda A; Stiff T; Sigaran U; Valenzuela MM; Ferguson Bennit HR; Moyron RB; Khan S; Wall NR
Pancreas; 2016 Jan; 45(1):101-9. PubMed ID: 26348467
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.
Shekhar TM; Green MM; Rayner DM; Miles MA; Cutts SM; Hawkins CJ
Mutat Res; 2015 Jul; 777():23-32. PubMed ID: 25916945
[TBL] [Abstract][Full Text] [Related]
17. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.
Brunckhorst MK; Lerner D; Wang S; Yu Q
Cancer Biol Ther; 2012 Jul; 13(9):804-11. PubMed ID: 22669575
[TBL] [Abstract][Full Text] [Related]
18. Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c.
Ling Q; Xu X; Wei X; Wang W; Zhou B; Wang B; Zheng S
J Exp Clin Cancer Res; 2011 Jun; 30(1):66. PubMed ID: 21714853
[TBL] [Abstract][Full Text] [Related]
19. Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.
Huang Y; Yang X; Xu T; Kong Q; Zhang Y; Shen Y; Wei Y; Wang G; Chang KJ
Int J Oncol; 2016 Jul; 49(1):153-63. PubMed ID: 27210546
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.
Hurwitz HI; Smith DC; Pitot HC; Brill JM; Chugh R; Rouits E; Rubin J; Strickler J; Vuagniaux G; Sorensen JM; Zanna C
Cancer Chemother Pharmacol; 2015 Apr; 75(4):851-9. PubMed ID: 25716544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
